Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

190.51 -4.05 (-2.08%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Nasdaq, S&P 500 Futures Rebound In New Trading Week But Rising Bond Yields Remain A Risk
US stocks are coming off a lackluster week and early indications suggest a reversal in sentiment in the new trading week. While rising bond yields could be a cause of concern, the recent weakness could... 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
4 Analysts Have This to Say About BeiGene
Via Benzinga
FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia
Via Benzinga
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
Via Benzinga
BeiGene Earnings Perspective: Return On Capital Employed
Via Benzinga
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
From BeiGene
Via Business Wire
Five Best And Worst Performing Healthcare Stocks In January 2023
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and... 
Via Talk Markets
What 5 Analyst Ratings Have To Say About BeiGene
Via Benzinga
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
From BeiGene
Via Business Wire
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
Draganfly To Rally Around 87%? Here Are 10 Other Analyst Forecasts For Friday
SVB Leerink raised the price target for BeiGene, Ltd. (NASDAQ: BGNE) from $236 to $300. SVB Leerink analyst Andrew Berens maintained an Outperform rating. BeiGene shares rose 2% to $279.90 in... 
Via Benzinga
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
From BeiGene
Via Business Wire
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
From BeiGene
Via Business Wire
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
From BeiGene
Via Business Wire
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
From BeiGene
Via Business Wire
These Were The Five Best And Worst Performing Large-Cap Stocks In Q4 2022
The year 2022 proved to be the worst calendar year for the S&P 500 since 2008. The benchmark index dropped more than 5% in December and almost 20% for the full year. Let’s take a look at the five best... 
Via Talk Markets
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific
Boston Scientific will pay $523 million for a 65% stake in Acotec Scientific, a Beijing medical device company. Boston Scientific said the acquisition will build up its presence in China, and it will... 
Via Talk Markets
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
From BeiGene
Via Business Wire
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors
From BeiGene
Via Business Wire
BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating
On Thursday, China-based BeiGene stock cleared that desired 80-plus benchmark, with a jump to 82 from 77 a day earlier. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.